239 related articles for article (PubMed ID: 35679540)
1. Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Soff GA; Ray-Coquard I; Rivera LJM; Fryzek J; Mullins M; Bylsma LC; Park JK
PLoS One; 2022; 17(6):e0257673. PubMed ID: 35679540
[TBL] [Abstract][Full Text] [Related]
2. A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Chen M; Li L; Xia Q; Chen X; Liao Z; Wang C; Shen B; Zhou M; Zhang Q; Zhang Y; Qian L; Yuan X; Wang Z; Xue C; An X; Liu B; Gu K; Hou M; Wang X; Wang W; Li E; Zhong J; Cheng J; Shu Y; Yang N; Wang H; Yang R; Liu T; Deng T; Ma F; Liao W; Qiu W; Chen Y; Chen X; Zhang M; Xu R; Li X; Feng J; Ba Y; Shi Y
Cancer; 2024 Apr; 130(S8):1524-1538. PubMed ID: 38515388
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
4. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia.
Al-Samkari H; Soff GA
Expert Rev Hematol; 2021 May; 14(5):437-448. PubMed ID: 33926362
[No Abstract] [Full Text] [Related]
5. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.
Demeter J; Istenes I; Fodor A; Paksi M; Dombi P; Valasinyószki E; Csomor J; Matolcsy A; Nagy ZG
Pathol Oncol Res; 2011 Mar; 17(1):141-3. PubMed ID: 20628840
[TBL] [Abstract][Full Text] [Related]
6. The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Levy B; Arnason JE; Bussel JB
Curr Opin Oncol; 2008 Nov; 20(6):690-6. PubMed ID: 18841052
[TBL] [Abstract][Full Text] [Related]
7. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
8. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
Sci Rep; 2018 Jan; 8(1):576. PubMed ID: 29330464
[TBL] [Abstract][Full Text] [Related]
10. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
11. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
Al-Samkari H; Parnes AD; Goodarzi K; Weitzman JI; Connors JM; Kuter DJ
Haematologica; 2021 Apr; 106(4):1148-1157. PubMed ID: 32499239
[TBL] [Abstract][Full Text] [Related]
12. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
Estcourt LJ; Malouf R; Doree C; Trivella M; Hopewell S; Birchall J
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012779. PubMed ID: 30221749
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.
Shin J; Kim MJ; Quan X; Kim JW; Lee S; Park S; Jeong JY; Yea K
BMC Cancer; 2023 May; 23(1):490. PubMed ID: 37259024
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
Song AB; Goodarzi K; Karp Leaf R; Kuter DJ; Al-Samkari H
Am J Hematol; 2021 Dec; 96(12):1563-1568. PubMed ID: 34453757
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
[TBL] [Abstract][Full Text] [Related]
17. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.
Catalá-López F; Corrales I; de la Fuente-Honrubia C; González-Bermejo D; Martín-Serrano G; Montero D; Saint-Gerons DM
Med Clin (Barc); 2015 Dec; 145(12):511-9. PubMed ID: 26051432
[TBL] [Abstract][Full Text] [Related]
18. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
Catalá-López F; Corrales I; Martín-Serrano G; Tobías A; Calvo G
Med Clin (Barc); 2012 Oct; 139(10):421-9. PubMed ID: 22266082
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A; Sholzberg M; Buckstein R
Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
Al-Samkari H
Blood Rev; 2024 Jan; 63():101139. PubMed ID: 37914568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
